Literature DB >> 18093753

Evaluation of antibody-ELISA and real-time RT-PCR for the diagnosis and profiling of bluetongue virus serotype 8 during the epidemic in Belgium in 2006.

Frank Vandenbussche1, Tine Vanbinst, Bart Verheyden, Wesley Van Dessel, Lien Demeestere, Philippe Houdart, Guido Bertels, Nicolas Praet, Dirk Berkvens, Koen Mintiens, Nesya Goris, Kris De Clercq.   

Abstract

In 2006 bluetongue (BT) emerged for the first time in North-Western Europe. Reliable diagnostic tools are essential in controlling BT but data on the diagnostic sensitivity (Se) and specificity (Sp) are often missing. This paper aims to describe and analyse the results obtained with the diagnostics used in Belgium during the 2006 BT crisis. The diagnosis was based on a combination of antibody detection (competitive ELISA, cELISA) and viral RNA detection by real-time RT-PCR (RT-qPCR). The performance of the cELISA as a diagnostic tool was assessed on field results obtained during the epidemic and previous surveillance campaigns. As the infectious status of the animals is unknown during an epidemic, a Bayesian analysis was performed. Both assays were found to be equally specific (RT-qPCR: 98.5%; cELISA: 98.2%) while the diagnostic sensitivity of the RT-qPCR (99.5%) was superior to that of the cELISA (87.8%). The assumption of RT-qPCR as standard of comparison during the bluetongue virus (BTV) epidemic proved valid based on the results of the Bayesian analysis. A ROC analysis of the cELISA, using RT-qPCR as standard of comparison, showed that the cut-off point with the highest accuracy occurred at a percentage negativity of 66, which is markedly higher than the cut-off proposed by the manufacturer. The analysis of the results was further extended to serological and molecular profiling and the possible use of profiling as a rapid epidemiological marker of the BTV in-field situation was assessed. A comparison of the serological profiles obtained before, during and at the end of the Belgian epidemic clearly showed the existence of an intermediate zone which appears soon after BTV (re)enters the population. The appearance or disappearance of this intermediate zone is correlated with virus circulation and provides valuable information, which would be entirely overlooked if only positive and negative results were considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18093753     DOI: 10.1016/j.vetmic.2007.10.029

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  20 in total

1.  Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep.

Authors:  Cristina C P Celma; Mark Boyce; Piet A van Rijn; Michael Eschbaumer; Kerstin Wernike; Bernd Hoffmann; Martin Beer; Andy Haegeman; Kris De Clercq; Polly Roy
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

2.  The most likely time and place of introduction of BTV8 into Belgian ruminants.

Authors:  Claude Saegerman; Philip Mellor; Aude Uyttenhoef; Jean-Baptiste Hanon; Nathalie Kirschvink; Eric Haubruge; Pierre Delcroix; Jean-Yves Houtain; Philippe Pourquier; Frank Vandenbussche; Bart Verheyden; Kris De Clercq; Guy Czaplicki
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

3.  Bluetongue virus in wild deer, Belgium, 2005-2008.

Authors:  Annick Linden; Fabien Gregoire; Adrien Nahayo; David Hanrez; Benedicte Mousset; Audrey Laurent Massart; Ilse De Leeuw; Elise Vandemeulebroucke; Frank Vandenbussche; Kris De Clercq
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

4.  Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.

Authors:  Jenna Anderson; Sara Hägglund; Emmanuel Bréard; Loic Comtet; Karin Lövgren Bengtsson; John Pringle; Stéphan Zientara; Jean Francois Valarcher
Journal:  Clin Vaccine Immunol       Date:  2013-05-29

5.  Pathological, serological, and virological findings in sheep infected simultaneously with Bluetongue, Peste-des-petits-ruminants, and Sheeppox viruses.

Authors:  Ozlem Ozmen; Mehmet Kale; Mehmet Haligur; Sibel Yavru
Journal:  Trop Anim Health Prod       Date:  2008-12-10       Impact factor: 1.559

6.  Anatomy of bluetongue virus serotype 8 epizootic wave, France, 2007-2008.

Authors:  Benoit Durand; Gina Zanella; Fabienne Biteau-Coroller; Caroline Locatelli; Florence Baurier; Cecile Simon; Eric Le Dréan; José Delaval; Eric Prengère; Véronique Beauté; Hélène Guis
Journal:  Emerg Infect Dis       Date:  2010-12       Impact factor: 6.883

7.  Bluetongue in Eurasian lynx.

Authors:  Thierry P Jauniaux; Kris E De Clercq; Dominique E Cassart; Seamus Kennedy; Frank E Vandenbussche; Elise L Vandemeulebroucke; Tine M Vanbinst; Bart I Verheyden; Nesya E Goris; Freddy L Coignoul
Journal:  Emerg Infect Dis       Date:  2008-09       Impact factor: 6.883

8.  Serologic screening for 13 infectious agents in roe deer (Capreolus capreolus) in Flanders.

Authors:  Paul Tavernier; Stanislas U Sys; Kris De Clercq; Ilse De Leeuw; Anne Brigitte Caij; Miet De Baere; Nick De Regge; David Fretin; Virginie Roupie; Marc Govaerts; Paul Heyman; Daisy Vanrompay; Lizi Yin; Isabelle Kalmar; Vanessa Suin; Bernard Brochier; Alexandre Dobly; Stéphane De Craeye; Sophie Roelandt; Els Goossens; Stefan Roels
Journal:  Infect Ecol Epidemiol       Date:  2015-11-24

9.  A dynamic spatio-temporal model to investigate the effect of cattle movements on the spread of bluetongue BTV-8 in Belgium.

Authors:  Chellafe Ensoy; Marc Aerts; Sarah Welby; Yves Van der Stede; Christel Faes
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

10.  Experimental bluetongue virus superinfection in calves previously immunized with bluetongue virus serotype 8.

Authors:  Ludovic Martinelle; Fabiana Dal Pozzo; Pierre Sarradin; Willem Van Campe; Ilse De Leeuw; Kris De Clercq; Christine Thys; Etienne Thiry; Claude Saegerman
Journal:  Vet Res       Date:  2016-07-28       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.